Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ETX-148
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025
Details : ETX-148 is a potential pan-hemophilia rebalancing agent. It utilizes e-therapeutics' GalOmic GalNAc-siRNA technology to silence novel gene targets in hepatocytes.
Product Name : ETX-148
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 05, 2025
Lead Product(s) : ETX-148
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable